Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles

Medicinal Chemistry Research

Volumn 22, Issue 3, 2013, Pages 1320-1329

  Patel, Navin B ^a   Khan, Imran H ^a   Pannecouque, Christophe ^b   De Clercq, Erik ^b  

^a VEER NARMAD SOUTH GUJARAT UNIVERSITY   (India)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1,2,4 Triazole; Anti HIV activity; Antimicrobial activity; Antimycobaterial activity; Benzothiazoles

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 (3 PYRIDYL) 5 (4 CHLORO PHENYL) 1,3,4 OXADIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 4 CHLORO) 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 4 METHYL 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 4 NITRO 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 BROMO 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 CHLORO 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 FLOURO 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 METHOXY 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 METHYL 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N 6 NITRO 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (3 PYRIDYL) 5 (4 CHLOROPHENYL) 4 (N(5,6 DICHLORO) 1,3 BENZOTHIAZOL 2 AMINO) 4H 1,2,4 TRIAZOLE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPICILLIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMYCOBACTERIAL AGENT; BENZOTHIAZOLE DERIVATIVE; GRISEOFULVIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BROTH DILUTION; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; FUNGAL STRAIN; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; MYCOBACTERIUM; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84874108718     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0129-4     Document Type: Article

References (27)

1. Ahmad Z, Sharma S, Khuller GK (2006a) Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 262(2):181-186
2. Ahmad Z, Sharma S, Khuller GK (2006b) The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 258(2):200-203
3. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48(12):4680-4686
4. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11:1805-1843
5. Camus JC, Pryor MJ, Médigue C, Cole ST (2002) Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148:2967-2973
6. Castagnolo D, Radi M, Dessi F, Manetti F, Saddi M, Meleddu R, De Logu A, Botta M (2009) Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis. Bioorg Med Chem Lett 19(8):2203-2205
7. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685):537-544
8. De Clercq E (2004) Anti-HIV chemotherapy: current state of the art. Med Chem Res 13:439-478
9. Freimuth WW (1996) Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol 394:279-289
10. Guardiola-Diaz HM, Foster LA, Mushrush D, Vaz AND (2001) Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem Pharmacol 61(12):1463-1470
11. Gutierrez-Lugo MT, Bewley CA (2008) Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem 51(9):2606-2612
12. Imamichi T (2004) Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 10(32):4039-4053
13. Janin YL (2007) Antituberculosis drugs: ten years of research. Bioorg Med Chem 15(7):2479-2513
14. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Béthune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile (R278474, rilpivirine. J Med Chem 48(6):1901-1909
15. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ, Sullivan JL (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 163(5):966-970
16. McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K, Kieser T, Gurcha SS, Besra GS, Munro AW (2002) Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 148:2937-2949
17. Morris S, Bai GH, Suffys P, Portilo-Gomez L, Fairchok M, Rouse D (1995) Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 171(4):954-960
18. Munro AW, McLean KJ, Marshall KR, Warman AJ, Lewis G, Roitel O, Sutcliffe MJ, Kemp CA, Modi S, Scrutton NS, Leys D (2003) Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis. Biochem Soc Trans 31:625-630
19. Patel NB, Khan IH (2011) Synthesis of 1,2,4-triazole derivatives containing benzothiazoles as pharmacologically active molecule. J Enzym Inhib Med Chem 26(4):527-534
20. Patel NB, Khan IH, Rajani SD (2010a) Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles. Eur J Med Chem 45:4293-4299
21. Patel NB, Khan IH, Rajani SD (2010b) Antimycobacterial and antimicrobial study of new 1,2,4-triazoles with benzothiazoles. Arch Pharm 343:692-699
22. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20(4):309-321
23. Rattan A (2000) Antimicrobials in laboratory medicine. Churchill B.I. Livingstone, New Delhi, pp 85-108
24. Saha A, Kumar R, Kumar R, Devakumar C (2010) Note development and assessment of green synthesis of hydrazides. Indian J Chem 49B:526-531
25. Seward HE, Roujeinikova A, McLean KJ, Munro AW, Leys DJ (2006) Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. Biol Chem 281(51):39437-39443
26. Wainberg MA, Sawyer JPC, Montaner JSG, Murphy RL, Kuritzkes DR, Raffi F (2005) Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir Ther 10(1):13-28
27. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen IW, Schleif WA, Sardana VV, Long WJ, Byrnes VW, Emini EA (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39:2602-2605